The modern breast implant was born in 1962, when two American plastic surgeons named Thomas Cronin and Frank Gerow developed the first silicone gel-filled device and implanted it in a patient in Houston, Texas. But the desire to augment breasts surgically stretches back much further, and the path from the earliest crude attempts to today’s devices is a story of medical ambition, serious harm, regulatory crisis, and slow improvement over more than a century.
The Earliest Experiments With Injection
Long before anyone designed an implantable device, doctors in the late 1800s and early 1900s tried to enlarge breasts by injecting materials directly into the tissue. The list of substances used reads like a hardware store inventory: paraffin, petroleum jelly, beeswax, shellac, and even epoxy resin were all injected into breast tissue in attempts at augmentation.1PubMed Central. The Evolution of Breast Implants These injections frequently caused devastating complications. Paraffin, one of the most commonly used materials, often triggered severe inflammatory reactions. The body would wall off the foreign substance, forming hard, painful lumps called paraffinomas. Infections, tissue death, and disfigurement were common outcomes.
During and after World War II, liquid silicone injections gained popularity in Japan, reportedly used first by or for sex workers who believed larger breasts would attract American servicemen. Industrial-grade silicone, sometimes mixed with other substances, was injected freely into the breasts. The practice spread to the United States and other countries through the 1950s and 1960s, often performed outside legitimate medical settings. The results were frequently catastrophic: silicone migrated through tissues, caused chronic inflammation, and led to infections that sometimes required mastectomy. Some women died. These disasters made it clear that simply injecting foreign material into the breast was not a viable path, and pushed surgeons toward the idea of a contained, implantable device.
Sponges, Teflon, and Other Solid Inserts
Before silicone gel implants arrived, surgeons in the 1950s experimented with solid and semi-solid synthetic materials placed inside the breast. These included polyurethane sponges, polytetrafluoroethylene (better known as Teflon), and a material called Ivalon sponge, which was made from polyvinyl alcohol formaldehyde.1PubMed Central. The Evolution of Breast Implants The thinking was reasonable enough: place a shaped piece of biocompatible material inside the breast to add volume. In practice, the body did not cooperate. Sponge-type implants had a particular problem: the body’s tissue would grow into the porous structure of the sponge, and over time the material would shrink, harden, and distort. Removing them was difficult because they became so enmeshed with surrounding tissue. Infection rates were high, and the cosmetic results deteriorated quickly.
These early solid implants were a dead end, but they taught surgeons something important. A successful breast implant would need a smooth, contained outer shell that the body could tolerate without aggressively growing into or attacking it. That lesson set the stage for the silicone era.
1962 and the Birth of the Silicone Gel Implant
The breakthrough came in 1962, when Thomas Cronin and Frank Gerow at Baylor College of Medicine created the first silicone gel breast implant. Their device was a thick silicone rubber shell filled with silicone gel, and it marked the beginning of what is generally considered the modern era of breast augmentation.2PubMed Central. The Evolution of Breast Implants – Section: Evolution of Silicone Implants The first patient to receive the implant was a dog named Esmeralda, used in preclinical testing, followed by the first human implantation in a woman named Timmie Jean Lindsey in March 1962 at Jefferson Davis Hospital in Houston.
The Cronin-Gerow implant was manufactured by Dow Corning and had a teardrop shape with a seam around the edge, somewhat like a sealed pouch. Early models also had Dacron patches on the back to help anchor the implant to the chest wall. While these first-generation devices were a huge leap forward compared to sponges and injections, they were far from perfect. The shells were relatively thick but prone to developing leaks over time, and the silicone gel inside was quite liquid, meaning that when a shell failed, the gel could spread into surrounding tissues.
Saline Implants Enter the Picture
Just two years after the first silicone gel implant, a French surgeon named Henri Arion patented a different approach: an inflatable implant filled with sterile saltwater. Arion’s saline implant was patented in 1964 and used in patients the following year.3PubMed Central. The Evolution of Breast Implants – Section: Evolution of Saline Implants The concept had an appealing safety advantage: if the shell ruptured, the body would simply absorb the harmless saltwater, unlike silicone gel which could linger in tissues and cause problems.
Saline implants also offered a practical surgical benefit. Because they could be inserted empty and then filled through a valve, the incision needed to place them was smaller than what silicone gel implants required. Surgeons could also fine-tune the volume during the operation, adjusting symmetry in real time. The trade-off was feel. Saline implants tend to feel firmer and less natural than silicone gel, and they are more prone to visible rippling, especially in thinner patients with less natural breast tissue to camouflage the device. This cosmetic limitation kept silicone gel implants dominant in the market through the 1970s and 1980s, though saline devices carved out a meaningful share and would become critically important when regulators stepped in.
Generations of Change Through the 1970s and 1980s
The silicone implant did not stay frozen in its original 1962 design. Manufacturers iterated rapidly through what are generally described as successive generations. In the 1970s, second-generation implants moved to thinner shells and more liquid gel in an effort to create a softer, more natural feel. Patients and surgeons liked the initial cosmetic results, but thinner shells meant higher rupture rates, and the runnier gel meant more problems when leaks occurred. Capsular contracture, a condition where the scar tissue the body naturally forms around any implant tightens and squeezes the device until the breast becomes hard and painful, was also a persistent issue across all early implant types.
By the mid-1980s, manufacturers had recognized these problems and began developing third-generation devices with improved shells and slightly more cohesive gel. Textured surfaces were introduced around this time as well, based on the observation that polyurethane-coated implants seemed to have lower rates of capsular contracture. The texturing was intended to disrupt the organized scar formation that leads to contracture, though the long-term evidence for this benefit turned out to be more complicated than early hopes suggested.
The 1992 FDA Moratorium
The most dramatic chapter in implant history arrived in the early 1990s. Throughout the late 1980s, a wave of lawsuits alleged that silicone breast implants caused a range of systemic diseases, including autoimmune disorders like lupus and rheumatoid arthritis. Media coverage was intense, and public fear grew rapidly. Under mounting pressure, the U.S. Food and Drug Administration concluded that the evidence supporting the safety and effectiveness of silicone breast implants was insufficient, and in January 1992 placed a temporary moratorium banning their use in the United States.4PubMed Central. History of breast implants: Back to the future
The moratorium did not ban breast augmentation altogether. Saline-filled implants remained available, and silicone gel implants could still be used in limited circumstances, such as breast reconstruction after mastectomy, but only as part of clinical studies. For cosmetic augmentation, saline became the only legal option in the U.S. for the next fourteen years. Other countries, including those in the European Union, did not follow the American ban, and silicone gel implants continued to be used and studied abroad throughout the moratorium period.
The legal fallout was enormous. Dow Corning, the original manufacturer of silicone gel implants, filed for bankruptcy in 1995 amid billions of dollars in litigation. A massive class-action settlement was eventually reached. But here is where the story takes an unexpected turn: the large epidemiological studies that followed the moratorium consistently failed to find a link between silicone breast implants and autoimmune disease. Multiple independent scientific panels, including one convened by the Institute of Medicine in 1999, reviewed the accumulated evidence and concluded that while silicone implants could cause local complications like rupture and capsular contracture, there was no convincing evidence that they caused systemic autoimmune diseases. The fear that drove the moratorium was, by the science’s own accounting, not supported.
The Return of Silicone and Fourth-Generation Devices
The FDA moratorium spurred manufacturers to redesign their products with stricter quality standards. Starting in the late 1980s and continuing through the 1990s, fourth-generation implants were developed under manufacturing criteria and quality controls far more rigorous than anything that came before, driven by legislative FDA changes enacted in 1988. These newer devices featured thick outer shells, roughly half a millimeter thick, and a more cohesive gel filler that was less likely to migrate if the shell failed. Manufacturers also began texturing the outer shells using techniques like salt-loss processing and imprint stamping, designed to allow tissue to grow into the irregular surface and reduce capsular contracture.4PubMed Central. History of breast implants: Back to the future
In 2006, the FDA lifted the moratorium and approved silicone gel implants from two manufacturers, Allergan and Mentor, for cosmetic use in women aged 22 and older. The approval came with conditions: both companies were required to conduct large, long-term post-approval studies tracking outcomes in thousands of patients over ten years. The 2006 re-approval marked a turning point. Within a few years, silicone gel implants had recaptured the majority of the U.S. market, and they remain the more popular choice today, largely because of their more natural feel compared to saline.
Breast Implant-Associated Anaplastic Large Cell Lymphoma
Just as the safety debate over autoimmune disease was settling, a new concern emerged. Starting in the late 1990s and gaining recognition through the 2000s and 2010s, a rare cancer called breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL, was identified in women with breast implants. This is not breast cancer but rather a type of lymphoma that develops in the scar tissue capsule surrounding the implant. The risk is strongly associated with textured-surface implants rather than smooth ones. The absolute risk remains very low, on the order of a few cases per million implanted devices per year, but the discovery led to a global recall of certain heavily textured implant models in 2019. Allergan’s Biocell textured implants were pulled from the market after being linked to the majority of confirmed BIA-ALCL cases worldwide.
The BIA-ALCL story is a useful reminder that “approved” does not mean “risk-free,” and that rare complications can take decades to emerge when the exposed population is large enough. For patients, the practical takeaway is that implant type matters: smooth implants appear to carry a much lower risk of this particular cancer, and anyone with textured implants should be aware of the symptoms, which typically include persistent swelling or fluid collection around the implant months or years after surgery.
Breast Implant Illness and the Ongoing Debate
Separate from BIA-ALCL, a growing number of patients have reported a constellation of symptoms they attribute to their breast implants, commonly referred to as breast implant illness, or BII. Symptoms described include chronic fatigue, joint pain, brain fog, hair loss, and rashes. Many patients report that their symptoms improve or resolve after explantation, the surgical removal of their implants.
The medical establishment’s relationship with BII is complicated. The FDA acknowledges patient-reported symptoms and has updated its guidance to require that patients receive better information about potential risks before surgery. Several studies have attempted to characterize BII, but the research is still in early stages, and no consistent biomarker or mechanism has been identified. The symptoms overlap heavily with common conditions like fibromyalgia and chronic fatigue syndrome, making it difficult to establish a direct causal link. Some researchers suspect that a subset of patients may have a genuine immunological sensitivity to silicone or other implant materials, but proving this at a population level has been elusive. What is clear is that thousands of patients experience real suffering, and the medical community has been slow to take their reports seriously, a pattern that echoes the early dismissal of autoimmune concerns in the 1990s before those were systematically studied.
How Augmentation Surgery Has Changed
Beyond the implant devices themselves, the surgical techniques used to place them have evolved dramatically. Early procedures typically placed the implant directly behind the breast tissue and in front of the chest muscle, a position called subglandular placement. This was simpler surgically but often produced less natural results and higher rates of visible rippling and capsular contracture. By the 1980s and 1990s, submuscular placement, where the implant sits partially or fully behind the pectoral muscle, became increasingly popular because it provided an additional layer of tissue coverage and tended to produce softer, more natural-looking results.
More recently, the “dual plane” technique has become widely adopted, combining elements of both approaches. The upper portion of the implant sits behind the muscle while the lower portion is covered only by breast tissue, allowing surgeons to tailor the result to each patient’s anatomy. Fat grafting, where a patient’s own fat is harvested via liposuction and injected into the breasts, has also emerged as either a complement to implants or a standalone augmentation method for patients seeking modest size increases without a foreign device. Incision locations have diversified too: the inframammary fold (the crease under the breast), the periareolar approach (around the edge of the areola), and the transaxillary route (through the armpit) each have trade-offs in terms of scarring, surgical access, and implant positioning options.
What Implants Look Like Today
A patient walking into a consultation in 2024 faces a range of choices that would have been unimaginable in the Cronin-Gerow era. Silicone gel implants now come in round and anatomical (teardrop) shapes, with varying degrees of gel cohesivity. The most cohesive versions, sometimes called “gummy bear” implants, hold their shape even if the shell is cut open, which reduces the risk of gel migration in the event of a rupture. Saline implants are still available and preferred by some patients, particularly those who want the reassurance that any leak will be immediately obvious as the affected breast deflates and the body harmlessly absorbs the saltwater.
Structured saline implants, a newer category, use internal baffles or nested shells to reduce the rippling that has historically been saline’s biggest cosmetic drawback. These devices aim to split the difference between the safety profile of saline and the more natural feel of silicone. Implant sizes are measured in cubic centimeters of volume rather than bra cup sizes, and profiles range from low to ultra-high, describing how far the implant projects forward relative to its base width. Surgeons use sizing systems and sometimes 3D imaging to help patients visualize outcomes before committing.
Regulatory requirements have also tightened. Since 2020, the FDA has required a boxed warning on all breast implants and mandated that patients receive a detailed checklist of risks before surgery, including information about BIA-ALCL, implant rupture, and the possibility of additional surgeries over a lifetime. Implants are not lifetime devices; the FDA and manufacturers generally advise that patients should expect to need at least one revision or replacement surgery at some point, with rupture rates increasing the longer an implant has been in place.